What is the recommended dose of mefenamic acid (nonsteroidal anti-inflammatory drug (NSAID)) for pediatric patients with fever?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mefenamic Acid Pediatric Dosing for Fever

The recommended dose of mefenamic acid for pediatric fever is 6 mg/kg per dose, given orally every 6-8 hours, though acetaminophen (15 mg/kg) or ibuprofen (10 mg/kg) should be used as first-line antipyretics instead. 1

Primary Recommendation: Use Acetaminophen or Ibuprofen First

  • Acetaminophen remains the preferred first-line antipyretic at 10-15 mg/kg per dose every 4-6 hours (maximum 60 mg/kg/day), particularly for infants under 6 months. 2
  • Ibuprofen is recommended at 10 mg/kg per dose every 6-8 hours for children ≥6 months of age. 2
  • NSAIDs like mefenamic acid should be reserved for pain management or chronic inflammatory conditions rather than simple fever control due to safety considerations. 1

Mefenamic Acid Dosing When Used

Standard Dosing

  • The established pediatric dose is 6 mg/kg per dose, administered orally. 1
  • Dosing interval follows typical NSAID patterns of every 6-8 hours, similar to ibuprofen. 2

Evidence Supporting This Dose

  • A 2022 randomized controlled trial demonstrated that mefenamic acid 6 mg/kg had comparable antipyretic efficacy to high-dose paracetamol (20 mg/kg), with mean time to normal temperature of 84.90±30.42 minutes. 1
  • Older studies from 1977-1978 suggested 4 mg/kg as the optimal antipyretic dose, though the more recent trial used 6 mg/kg with good safety profile. 3, 4

Clinical Context and Limitations

Why Mefenamic Acid Is Not First-Line

  • The American Academy of Pediatrics guidelines for pediatric fever management do not include mefenamic acid in their recommended antipyretic agents. 2
  • Standard guidelines emphasize acetaminophen and ibuprofen as the evidence-based antipyretics with established safety profiles in children. 2
  • The 2022 trial concluded that "mefenamic acid may be avoided as an antipyretic and spared for pain and anti-inflammatory indications." 1

When Mefenamic Acid Might Be Considered

  • Geographic regions where this medication is commonly available and approved for pediatric use. 1
  • Situations where both pain control and fever reduction are needed simultaneously.
  • Cases where acetaminophen and ibuprofen are contraindicated or unavailable.

Age-Specific Considerations

Infants Under 6 Months

  • Acetaminophen is the only recommended antipyretic, with ibuprofen generally not recommended for this age group. 2
  • Mefenamic acid has even less safety data in young infants and should be avoided.

Children 6 Months and Older

  • Both acetaminophen and ibuprofen are appropriate first-line options. 2
  • If mefenamic acid is used, the 6 mg/kg dose applies across pediatric age ranges based on available evidence. 1

Safety and Monitoring

Adverse Effects

  • The 2022 trial reported negligible adverse effects with mefenamic acid 6 mg/kg, though the sample size was limited (n=159). 1
  • As with all NSAIDs, monitor for gastrointestinal symptoms, renal function concerns, and bleeding risk.

Duration of Action

  • Mefenamic acid showed a trend toward longer duration before next fever spike (8.82±3.83 hours) compared to standard-dose paracetamol (5.07±2.66 hours), though this was not statistically significant. 1

Common Pitfalls to Avoid

  • Do not use mefenamic acid as routine first-line therapy for simple fever—reserve it for specific indications. 1
  • Do not exceed recommended NSAID dosing intervals; maintain at least 6-8 hours between doses.
  • Avoid NSAIDs in children with dehydration, renal impairment, or bleeding disorders.
  • Do not use in infants under 6 months of age where safety data is lacking.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.